Antiviral Stewardship in Transplantation DOI Creative Commons

Sruthi Bonda,

Sonya Trinh, Jonathan Hand

и другие.

Viruses, Год журнала: 2024, Номер 16(12), С. 1884 - 1884

Опубликована: Дек. 5, 2024

Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. there is a growing interest studying practices patients, optimal have not clearly established. A component ASPs, antiviral (AVS), specifically targeting cytomegalovirus (CMV), more recently described. Understanding AVS opportunities interventions particularly important recipients, given morbidity mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, resistance, costs disease medications, as well drug toxicities. This review highlights CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, BK polyomavirus patients.

Язык: Английский

Dual therapy with remdesivir plus extended nirmatrelvir/ritonavir in immunocompromised and critically ill patient with suspected persistent COVID-19 infection: Case report DOI

Arturo Gámiz Rejano,

Teresa López-Viñau, Charlotte Martin

и другие.

Medicina Intensiva, Год журнала: 2025, Номер 49(3), С. 174 - 177

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art” DOI

Marcial Delgado‐Fernández,

Juan Diego Ruíz-Mesa,

Almudena Rojas-González

и другие.

Enfermedades Infecciosas y Microbiología Clínica, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients DOI
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska

и другие.

Current Opinion in Infectious Diseases, Год журнала: 2024, Номер 37(6), С. 506 - 517

Опубликована: Окт. 23, 2024

Purpose of review The purpose this is to report the available evidence regarding use combination regimens antivirals and/or antibody-based therapy in treatment SARS-CoV-2 immunocompromised patients. Recent findings Literature search identified 24 articles, excluding single case reports, which included mainly patients with hematological malignancies B-cell depletion. Data were divided based on timing and reason for administration treatment, that is, early prevent progression severe COVID-19 prolonged or relapsed infection. We described treated populations, duration composition treatment. briefly addressed new options we proposed an algorithm management infection affected by malignancies. Summary Combination seems effective (73–100%) well tolerated (<5% reported bradycardia, hepatotoxicity, neutropenia) strategy treating prolonged/relapsed infections host, although its optimal cannot be defined currently evidence. role as at a high risk disease/persistent shedding requires further from comparison monotherapy, even though efficacy was combinations plus mAbs previous viral variants.

Язык: Английский

Процитировано

2

Dual therapy with remdesivir plus extended nirmatrelvir/ritonavir in immunocompromised and critically ill patient with suspected persistent COVID-19 infection: Case report DOI

Arturo Gámiz Rejano,

Teresa López-Viñau, Charlotte Martin

и другие.

Medicina Intensiva (English Edition), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Язык: Английский

Процитировано

1

COVID -19: On the threshold of the fifth year. The situation in Spain DOI Creative Commons
Fernando Rodríguez‐Artalejo, Julián Ruiz‐Galiana, Rafael Cantón

и другие.

Revista Española de Quimioterapia, Год журнала: 2023, Номер 37(1), С. 17 - 28

Опубликована: Ноя. 27, 2023

Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising two Omicron BA.2 sublineages with mutations genes encoding spicule proteins that could increase binding ACE2 receptor be more prone immune escape. Faced these, 3 pharmaceutical companies have developed vaccines adapted XBB.1.5 sublineage already available for administration our setting risks should not different those previous mRNA clearly favorable benefit/risk ratios. They applied patients potential poor evolution collectives a particular relationship proximity them. Their application understood only perspective individual convenience but also collective responsibility. The most convenient seems simultaneous immunization influenza environment. In therapeutic aspect, there is little expect right now antisera, known antiviral drugs still indicated, although their efficacy will reevaluated due impact on populations mostly immunized better prognosis than past. opinion, it necessary continue make reasonable timely use masks other non-pharmacological means protection.

Язык: Английский

Процитировано

3

Antiviral treatment for SARS-CoV-2 infection in the current situation: a position paper of the Spanish Society of Emergency Medicine (SEMES) DOI Open Access
Juan González del Castillo,

Amparo Fernández-Simón Almela,

Javier Jacob

и другие.

Emergencias, Год журнала: 2024, Номер unknown

Опубликована: Апрель 16, 2024

COVID-19 continues to pose a significant threat: mortality stands at nearly twice that of influenza, and the incidence rate is growing as population's vaccination decreases, particularly in Spain other areas Europe. Given this situation, it vitally important know whether medical protocols are consistent appropriately implemented by health care staff interest preventing possible inefficiency or inequity. Physicians from hospital emergency departments met study their hospitals' usual clinical practices for managing SARS-CoV-2 infection determine expert opinions on use antiviral agents. The participating physicians then reached consensus evidencebased recommendations strategies would optimize treatment.

Язык: Английский

Процитировано

0

COVID-19 in patients with haematologic malignancies: Effect of RNAemia on clinical outcome in vaccinated patients DOI Creative Commons
Javier Martín‐Escolano,

Sonsoles Salto-Alejandre,

Carmen Infante-Domínguez

и другие.

International Journal of Infectious Diseases, Год журнала: 2024, Номер 146, С. 107163 - 107163

Опубликована: Июль 3, 2024

Язык: Английский

Процитировано

0

Antiviral Stewardship in Transplantation DOI Creative Commons

Sruthi Bonda,

Sonya Trinh, Jonathan Hand

и другие.

Viruses, Год журнала: 2024, Номер 16(12), С. 1884 - 1884

Опубликована: Дек. 5, 2024

Though antimicrobial stewardship programs (ASPs) are required for hospitals, the involvement of transplant recipients in programmatic interventions, protocols, and metrics has historically been limited. there is a growing interest studying practices patients, optimal have not clearly established. A component ASPs, antiviral (AVS), specifically targeting cytomegalovirus (CMV), more recently described. Understanding AVS opportunities interventions particularly important recipients, given morbidity mortality associated with viral infections, challenging clinical syndromes, ultrasensitive molecular diagnostic assays, resistance, costs disease medications, as well drug toxicities. This review highlights CMV, EBV, HSV, VZV, SARS-CoV-2, respiratory syncytial virus, BK polyomavirus patients.

Язык: Английский

Процитировано

0